Directory · KR
Biotechnology Research in South Korea
A register of firms and the professionals working at them in the Biotechnology Research sector based in South Korea. Browse the public index, then filter or export on Kipplo.
Companies
299 on file
Kh Medical
KH Medical is a trailblazing force in the global healthcare landscape, committed to revolutionizing access to high-quality diagnostics for all, particularly in underserved low- and middle-income countries. From its inception, KH Medical has pursued a mission to level the playing field in healthcare, forging powerful alliances with governments, industry leaders, and international organizations worldwide. With a robust portfolio of proprietary technologies, KH Medical stands at the forefront of innovation, uniquely capable of covering both animal and human diagnostics. Our expertise spans the entire spectrum of diagnostic solutions, from raw materials for diagnostic reagents to cutting-edge diagnostic kits, molecular diagnostic extraction equipment, PCR systems, and immunofluorescence devices. KH Medical excels in the development and production of a wide range of high-performance products, including Rapid Tests, FIA Tests, extraction reagents, and PCR reagents, serving both veterinary and human health sectors. Our commitment to excellence is underscored by our ISO 13485 and GMP certifications, which stand as a testament to our relentless focus on quality and continuous improvement. KH Medical is not just a company; it is a beacon of innovation, driven by a vision to ensure that everyone, regardless of their circumstances, has access to the best possible diagnostic tools. By simultaneously advancing human and animal health diagnostics, we are redefining what’s possible in global healthcare.
11 to 50 staff
Kobiolabs Inc
Global Top 10 Player in Microbiome Therapeutics,
51 to 200 staff
Medpacto
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer. The leading drug candidate is Vactosertib, an orally bioavailable small-molecule inhibitor of the TGF-β type I receptor (TβRI) currently in phaseⅡ clinical trials with global pharmaceutical companies such as Merck and AstraZeneca. Vactosertib inhibits transforming growth factor-beta (TGF-β) pathway signaling, which is known to promote the metastasis and proliferation of cancer cells by modulating the tumor microenvironment. Vactosertib plays a synergistic role in improving the response to various therapies by inhibiting immune-suppressive TGF-β activity and suppressing the resistance mechanism of cancer stem cells. MedPacto is currently conducting combination trials with Vactosertib targeting several cancer indications including colorectal cancer, pancreatic cancer, sarcomas, NSCLC, bladder cancer, and gastric cancer. Additionally, MedPacto is currently developing MP005A, a new antibody therapeutics targeting BAG2 protein which promotes tumor formation and lung metastasis by binding the enzymes that regulate the tumor microenvironment in cancer development, and MP005D, a diagnostic kit that can detect BAG2 genes.
51 to 200 staff
Naturalendo Tech. Co., Ltd
Naturalendo Tech Co, Ltd. is a bio-tech company certified by the Korean government, specializing in bio-sciences, herbs, and endocrinology. For over a decade, the company has taken traditional oriental medicine and continuously developed its product line. Mission: Naturalendo Tech, world’s best biotech company in natural pharmaceuticals and novel herbal ingredient industry, will contribute for the betterment of human health and wellness based on our technology of endocrinology, gene reporter vector design, herbal medicine screening, and drug delivery. Business lines: Novel Functional Ingredients based on expertised R&D Technology Proprietary Standardized Novel Phytoestrgen: EstroG-100 Human Growth Hormone: IGF-1 Secretaogue Environment Hormone Disruptor DPP-IV Inhibiting Formula: Immune Enhancing Formula: Wellmune New Product Development Trans-dermal Drug Delivery System (TDDS) Anti-atopic dermatitis and Anti-acne Formula: Derma A2 Others
51 to 200 staff
Oscotec Inc
At Oscotec, our mission is to create values by translating cutting edge science into innovative medicines for clinically unmet needs”
51 to 200 staff
Bio Design Lab
We are Bio Design Lab, a South Korean startup developing novel retro- and lentiviral vector platforms that are safer than existing vectors and with high transduction efficiency – the foundation of effective gene, cell, and immunotherapies. With our RetroNext and LentiNext platforms, we are redefining the standards of safety, efficiency, and productivity. Founded in 2018, our mission is to facilitate and accelerate the development of next-generation biopharmaceuticals for currently incurable diseases.
11 to 50 staff
Cj Bio Animal Nutrition & Health
Technologies inspired by nature that gives back to nature. Sustainable life and healthy Earth. This is the philosophy that drives CJ BIO
501 to 1000 staff
Clinomics
The Page for The Leading Company in Precision Medicine for Genome-Based Life, Medical, and Health Care.
51 to 200 staff
Kolon Biotech, Inc
Kolon Biotech provides CDMO services fully engaged in cell & gene therapy that enable successful development of biological therapeutics. Our CDMO service fulfills the established project objectives and works towards the satisfaction of clients. Also, we meet the demands for manufacturing capacity and flexibility by using a manufacturing platform named SACS (Semi-Automated & Closed System) in a cGMP compliant facility. We provide end-to-end CDMO service or each service chosen by clients for what they need (e.g. Process development, Production, QC test, etc.).
51 to 200 staff
Pharmcadd
PharmCADD is a company designed to accelerate drug discovery meanwhile performing a design without building or maintaining the infrastructure associated with high-performance computational resources. The platform for both the design and discovery in the PharmCADD is composed of the state-of-the art technology: AI (Artificial intelligence), Molecular Dynamics (MD), Quantum Calculation (QC), and Network theory. AI, which is data-derived technology emerges as a new trend which could potentially be very revolutionary in our modern world. It enables customers to accelerate the search for a certain or specific drug candidate in the vast existence of chemical space. On the other hand, MD and quantum calculation, physics-based technology, enables the customers to characterize potential drug candidates more precisely. The effective combination of the data-derived and physics-based technologies leads to more accurate and speedier drug discovery.
51 to 200 staff
Aryballe
Aryballe combines biochemistry, advanced optics and machine learning to mimic the human sense of smell. Aryballe’s unique software and data solutions provide odor display and analysis that helps leaders in the automotive, food & beverage, consumer appliance and flavor & fragrance industries make smarter and more informed business decisions. In addition, Aryballe's digital olfaction solutions help companies improve user experiences with applications in the automotive and consumer appliance markets. The company is headquartered in France and with commercial operations in the USA and Korea.
51 to 200 staff
Bbhc-Stri
bBHC Stem Cell Treatment & Research Institute discovered the newly Elicited pluripotent Stem Cell without side effects which is called nEPS. We've been differentiated nEPS into endoderm,mesoderm and ectoderm. Our goal is overcome to incurable diseas using in nEPS.
11 to 50 staff
Cyrus Therapeutics
Cyrus Therapeutics is a leading biotechnology company that is discovering and developing innovative medicines to conquer chronic or life-threatening diseases with high unmet needs. We are committed to making our mission—‘drugging the undruggable targets’—possible with small molecule drugs as well as new chemical modalities such as targeted protein degraders.
11 to 50 staff
E Green Global
Lab to Farm, a platform tissue culture tech company E Green Global (EGG), an agri-tech company that utilizes plant factory platform, has developed a disruptive technology that overcomes the limitations of the current seed potato supply system and shall lead the global seed potato market as the forerunner. EGG is the ONLY company that has successfully enabled “Lab to Farm” seed potatoes on a global scale. EGG has established the plant factory platform – virus-free Microtubers (bean-sized seed potato) are mass produced in bio-secured lab with environmental control system via in vitro (tissue culturing of plantlets in sterilized vessels), then are directly planted in the open field to produce virus-free high quality seed potatoes in a shorter span of time compared to the conventional method (conventional method requires five years, while EGG’s method requires only one or two) at a competitive price and productivity. “Cheaper, better and more!”
51 to 200 staff
Eutilex
Eutilex is a KOSDAQ listed company that researches and develops new drugs with a focus on immunotherapy
51 to 200 staff
Illimis Therapeutics
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
11 to 50 staff
Inexoplat Inc
Life's moments are precious, and we seize every opportunity to make them count. We pioneer immune-based therapies, setting the standard for transformative cancer treatments, providing hope to patients and striving to improve their quality of life.
1 to 10 staff
L&j Bio Usa, Inc
L&J Bio is committed to developing therapeutic proteins for neurodegenerative diseases through our Dual Action Therapy(DAT) Platform. We have developed innovative therapeutics for Alzheimer's disease through the application of our fusion proteins and implementing DAT to target both amyloid beta and phosphorylated tau proteins. Our mission is to provide safe and effective therapies for patients with serious illnesses. Headquarters and research institute/cGMP facility(future) is located in Maryland, United States, while research institute/office is in Seoul, South Korea. U.S. patent granted in 2024 and IND submission planned for Q1 2026 and Phase I to begin shortly after.
11 to 50 staff
Mxt Biotech
MxT biotech, a Korea University spin-out, is a startup focused on developing transformative microuidic gene delivery platforms for CGT developments.
11 to 50 staff
Panolos Bioscience
Panolos Bioscience is a frontrunner in structure-based protein design and development, with a focus on multi-specific drug development. We specialize in creating anti-angiogenic therapies targeting cancer, autoimmune, and rare diseases. Our proprietary "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific) technology" features a VEGF receptor backbone, enabling the creation of mono- or multi-specific antibody therapeutics with enhanced efficacy. Starting October 2023, PB101 using αART technology is enrolling for Phase I which is manufactured by Samsung Biologics based on a CDMO partnership. Panolos attracted a development partnership with Kelun-Biotech for PB203 (aka, PKB01), and formed the strategic alliance and CDMO partnership with Chime Biologics for the same. Panolos is developing various pipelines targeting PD-L1, EGFR, and TGF-beta(b) To support our ongoing development, Panolos Bioscience raised $18 million in Series A funding and is currently seeking a Series B Bridge investment of $20 million in 2023.
11 to 50 staff
Pin Therapeutics, Inc
Creating Therapeutic Products Degrading Disease-causing Proteins"
11 to 50 staff
Therabest
Therabest is a biopharmaceutical company that develops iPSC-derived immune cells. Our mission is to provide the benefits of cell therapy to many patients. We established a robust process that manufacture Armored iPSC CAR-NK, off-the-shelf cell products using our exclusive technology. Currently, our main pipeline is CD19 (Lymphoid tumor) and Muc1c (Solid tumor). We plan to expand our pipeline through collaboration with companies that own tumor target scFv.
51 to 200 staff
Undbio Pharma Co., Ltd
Inspire a healthier world, and use platform technology skillset to help humanity for a healthy, disease-free world. To be a company that can provide opportunities to achieve and improve the quality of human life
11 to 50 staff
Upstreambio
The Hub of Global Biotechnology, Upstreambio, Inc.
1 to 10 staff
Attislab
Our products are designed and developed by highly trained, world class scientists to streamline research protocols, reduce experimental variability, and increase the accuracy of results. We develop our product lines to support entire experimental workflows, from cell isolation through characterization, expansion, differentiation, maintenance and storage, and are always looking for ways to further support our customers through training, knowledge and new products.
1 to 10 staff
Dr.Asahan
Dr.ASAHAN’s mission is to lead the new generation of food industry based on the planet and rethink old-fashioned nutrition system by focusing on microbiome. We strongly believed that our passion can make a healthy impact on human, society and planet in a better way. Our breakthrough technology enables the world’s transition to sustainable plant-based food system. The key ingredient is Vegan Probiotics Liquid brought from the nature. This magical liquid has limitless possibility from creating plant-based protein to innovating better microbiota food. Adaptable for every food industry from juice to meat at affordable cost and actionable solution for reducing the planet’s burden. Be the first mover with Dr.ASAHAN. The paradigm shift is happening now. For more info : drasahan@asahan.kr
11 to 50 staff
Jlk
JLK is an Artificial Intelligence based medical and security solutions company having it’s head office in South Korea. Founded in 2014 and being one of the most highly funded AI startups in Korea, we are on a mission to create AI solutions for a better life. Our medical solution 'AIHuB’, supports the diagnosis of 37 diseases in 14 body while being seamlessly connected to all existing imaging diagnosis systems. Our AI security solution automatically detects objects such as weapons and storage devices to ensure protection of public safety and corporate intelligence.
51 to 200 staff
Koram Biotech & Koram Biogen Corp
For more than three decades, Koram has provided Korean researchers and life sciences manufacturers with high quality research reagents, certified biological & molecular reference materials and customized GMP solutions as well as laboratory consumables and instruments to accelerate biological understanding and enable breakthrough research in Korea. Koram, one of Korea’s largest life science distributors, is committed to helping our customers achieve their research objectives with comprehensive technical support, responsive customer care and reliable cold chain logistics. With the extensive sales network of 8 branch offices and 8 distributors, Koram Biotech and Koram Biogen have assisted and supported Korean researchers in academia, gov’t institutions and hospitals as well as biotech and pharmaceutical companies for more than three decades. Principal Suppliers & Business Partners include: American Type Culture Collection (ATCC) Cell Signaling Technology (CST) New England Biolabs (NEB) Santa Cruz Biotechnology (SCBT) OriGene Technologies (Origene) Proteintech (PTGLab, HumanKine, ChromoTek) Eppendorf Emulate Cayman Chemical & Matreya LGC Clinical Diagnostics, SeraCare, KPL, The Native Antigen Company,(TNAC), Virusys Eurogentec & Anaspec, Kaneka Company Signalchem Diagnostics SinoBiological & Signalchem Biotech ZeptoMetrix Cellecta Labcon And a whole lot more. If you are looking for business partners and/or distribution partners to explore South Korea life sciences markets, please contact us at koram@korambiotech.com
51 to 200 staff
Md Healthcare Inc
MD Healthcare Inc. is a microbiome-based precision medicine venture established in Seoul, South Korea in 2014. We have conducted metagenomic analysis of tens of thousands of clinical samples and found that microbial extracellular vesicles (EVs) are powerful biomarkers for disease diagnosis and potent therapeutic agents. Using our proprietary microbial EV postbiotic technology, we are developing a variety of drug pipelines, diagnostic kits, and personalized healthcare services. By harnessing our microbial EV technology, we are developing pre-clinical core drug pipelines for immuno-oncology, respiratory, GI, skin, and CNS disease treatment in addition to AI-driven non-invasive diagnostic tools for various chronic diseases.
11 to 50 staff
Nanohelix Co., Ltd
NanoHelix Co, Ltd. is a manufacturer and supplier of highly qualified molecular biological reagents and raw materials for molecular diagnostics. We also specialized in customized production of enzymes for molecular diagnostic and provide customized products- OEM Business, Contract Manufacturer, Custom Development - Technologies for MDx - International Quality Standard (ISO13485:2016)- Flexible Production Capability (10+ years experience) We supply over 70% of qRT-PCR enzymes for COVID-19 diagnostics test in South Korea. Our partners are major molecular diagnostics companies.
11 to 50 staff
Pathway Intermediates
Pathway Intermediates is the global animal nutrition company, dedicated to research and development.
51 to 200 staff
Pure&k Inc
Single Use System.
1 to 10 staff
Dt&c Bio Group
At Dt & C Bio Group, we are proud to offer a comprehensive suite of end-to-end CRO services that cater to every aspect of clinical and non-clinical trials. As Korea's first One-Stop CRO, we strive to deliver a differentiated strategy that ensures the utmost efficiency and success throughout the trial process. With the synergized coordination of our subsidiaries Dt & CRO, Huscience, and Safesoft, our partners gain access to a powerhouse of integrated services that streamline the trial management process, reduce timelines, and enhance overall efficiency.
501 to 1000 staff
Gene Story Korea Inc
DNA. AI, Big data, Bio, Education.
11 to 50 staff
Helixrus, Inc
A digital multi-omics healthcare company
1 to 10 staff
Mycel Inc
MYCEL is a Korean white-bio startup creating biodegradable mycelium-based materials. By controlling growth conditions, it offers sustainable, high-performance alternatives for fashion, interiors, and mobility industries.
11 to 50 staff
Nutrasource Asia
Nutrasource is a full-service contract research organization (CRO) that helps health companies bring products to market with strong science and regulatory confidence - from concept to claim. Through our vertically-integrated service platform, Nutrasource is your one-stop shop for international regulatory, clinical, and product testing solutions for dietary supplements, pharmaceuticals, and everything in between. As your virtual R&D department, we will help you tackle your toughest scientific problems so you can sell safe, effective, high-quality products to improve healthcare globally. Originally established as a diagnostic test provider nearly two decades ago, Nutrasource has since grown from a single desk to a global CRO employing over 100 staff across four sites in North America. By focusing first and foremost on the needs of our customers, we are proud to have helped hundreds of clients develop, launch, and market health products across the globe.
1 to 10 staff
Ubix Therapeutics, Inc
Saving Lives Through Innovations in Targeted Protein Degradation (TPD) Therapeutics. Ubix Therapeutics is a clinical-stage biotechnology company with comprehensive capabilities in TPD therapeutics, spanning from discovery to clinical studies. Our proprietary TPD platform technology, Degraducer®, harnesses the body’s natural protein degradation machinery to eliminate diseased proteins, achieving near-complete inactivation of disease-causing pathways. We have established a robust, wholly owned and partnered degrader pipeline focused on targeted and immuno-oncology areas. Our wholly owned programs include: • UBX-303-1, a Phase 1-stage, potential best-in-class BTK degrader for treating relapsed or refractory B-cell malignancies. • UBX-106, a preclinical-stage, potential first-in-class SHP2 degrader designed to treat a broad spectrum of MAPK signaling-driven solid tumors. Additionally, the IND-enabling study for UBX-103, AR degrader program which was out-licensed to Yuhan in July 2024, is currently underway. We believe our degrader programs can effectively address a broad range of drug resistance mutations and overcome residual activation of disease-causing signaling pathways. Our growing pipeline also includes programs targeting difficult-to-address proteins and the development of degrader-antibody conjugates. For more information, please visit http://en.ubixtrx.com/ or contact us at info@ubixtrx.com.
11 to 50 staff
Vaxdigm
Vaxdigm is a biotechnology company focused on the development of improved vaccines and future vaccines.
1 to 10 staff
Anterogen
Anterogen is a bio-venture company specializing in research and development of cell therapy products and orphan drugs using adult stem cells. Established a research institute in Boston in Anterogen began commercializing products using adipose-derived stem cells for the first time in Korea. In January 2012, we obtained a market authorization of Cupistem® injection as an adipose-derived stem cell therapy product for the first time in the world. Anterogen, an emerging global leader in the field of cell therapy products, has developed Adipocell® (for the treatment of depressed scar), Queencell® (for the regeneration of subcutaneous adipose tissue) and Cupistem® injection (for the treatment of Crohn's fistula) with accumulated experiences and R&D technology in stem cell therapy.
11 to 50 staff
Aptamer Sciences Inc
Aptamer Sciences Inc. is a privately held biotech company focused on commercializing cutting-edge technologies for analysis of proteins, based on its proprietary aptamer technology platforms. Aptamer Sciences is dedicated to develop the aptamer technologies to generate high quality aptamer and in broad applications of research, diagnosis and therapeutics. Compared to conventional aptamer generating technologies, Aptamer Sciences has developed advanced aptamer technologies and thus can generate aptamers more efficiently with superior binding affinity. Aptamer Sciences has ongoing collaboration relationships with several industry partners. The Company also has research collaboration with several universities, hospitals and research organizations. Aptamer Sciences was founded in 2011 by researchers from POSTECH BIOTECH CENTER and is based in Pohang, South Korea. Aptamer Sciences is currently funded by aptamer service revenue and grants, as well as by investments from strategic investors.
11 to 50 staff
Aribio
AriBio is a clinical-stage biotech company located in Seongnam, South Korea focused on developing novel therapeutics for neurodegenerative diseases. The US office is located in San Diego managing global clinical operations and regulatory affairs. The lead asset, AR1001, is entering a global phase 3 program this year.
51 to 200 staff
Bertis Inc
BERTIS Inc.'s proteomics technology provides diagnostic services that detect cancer and various diseases in the early stages. Proteomics is a field that studies the roles of various proteins, their relationships, and their characteristics, and that can research proteins directly involved in disease occurrence and progression, using technology simultaneously analyze hundreds of proteins as accurate and exquisite. About 10 years ago, when there was no interest in proteomics in Korea, BERTIS Inc. pursued proteomics scientific research after seeing the global scaled potential. As a result, We have secured unique technology based on 25 million protein big data and A. I. and have grown into a leading proteomics company in Korea. And now, we are working hard to go beyond the Republic of Korea into a global representative proteomics company. We constantly communicate and endeavor with experts representing each field, including physicians, chemists, biologists, and engineers.
11 to 50 staff
Bioapplications Inc
BioApp was established in 2011 based on POSTECH's plant biotechnology. It has achieved significant milestones, being the first to accomplish various achievements in both Korea and globally. Notably, the HERBAVAC™ CSF Green Marker vaccine, the world's inaugural plant-based classical swine fever vaccine, has been approved. BioApp aims to contribute to eliminating classical swine fever by achieving CSF-free status in Korea and entering the global market. Beyond animal vaccines, BioApp is engaged in developing vaccines for COVID-19, Zika, and dementia prevention. The company strives to establish a green vaccine production system to ensure swift delivery of secure and efficient vaccines, enhancing vaccine self-sufficiency to safeguard public health from severe infectious diseases.
51 to 200 staff
Coree Company
COREE company is established in 2001 with its principal office located in Hong Kong and holding 15 subsidiaries under its umbrella. We are a fully integrated bio platform company engaged in developing personalized medicine(precision medicine) and nutrition & healthcare products for disease treatment and prevention that considers the individual variability in genetics, environment, and lifestyle for each patient. In addition, COREE Company is a global leader in infant care service, pharmaceuticals and research and technology. The COREE Company pursues its main competency in the area of research, manufacturing and distribution of high standard "nutritional and pharmaceutical" products. Ofmom® is the principal brand under which we sell our infant formula products and probiotic supplements in Italy, China, Korea and the US. Throughout our international presence, we have grown to four brand centers and four R&D centers in Italy, China, Korea and the US. COREE Company is part of Hanmi Science group of companies. It is the largest pharmaceutical company in Korea, selling over 400 products worldwide since 1973.
501 to 1000 staff
Daone Chemical Co., Ltd
Daone Chemical Co,Ltd is one of leading manufacturer of Veterinary Medicine, Feed additives and Vitamin & Mineral premix. DaOne Chemical Co, Ltd.’s management philosophy rests on the principle of three 3T(Trust, Together, Tomorrow).It embodies the will to flourish together with its clients by producing future oriented, high-quality, innovative products as well as the will to rely on its foundation of trust management in order to satisfy its clients. DaOne Chemical Co, Ltd. will strive to become the leading company in eco-friendly pursuit in livestock industry by endlessly challenging itself as well as through creative and continuous R&D, thus generating future-oriented product lines and contributing to the production of safe, high quality feed and other livestock related products.
51 to 200 staff
Exopert
EXoPERT is a biotech company focusing on detecting cancer early by liquid biopsy. Founded in 2018, EXoPERT is developing a Novel Liquid biopsy technology that detects cancer at an early stage, and we aim to expand our impact in healthcare through continued research and development. We are using our exosome platform to detect serious diseases early by a single draw of blood. For more information, please visit exopert.com.
11 to 50 staff
Genealogy
Genealogy is a leading computational genomics company, harnessing the power of its proprietary artificial intelligence to deliver a rapid, high-quality analysis of large genomics data sets at a fraction of the cost of traditional methods.
11 to 50 staff
